Adefovir Dipivoxil/Lamivudine

阿德福韦酯/拉米夫定

Report date: 2022/12/07 17:51:51

Base Information

Drug NameAdefovir Dipivoxil/Lamivudine
Drug Alias Name拉米夫定/阿德福韦酯Adefovir Dipivoxil and LamivudineLamivudine/Adefovir DipivoxilLamivudine and Adefovir Dipivoxil
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionImmunostimulantsHBV DNA Polymerase inhibitorsReverse transcriptase inhibitors
TargetsReverse transcriptaseHBV DNA Polymerase
Therapy Area/IndicationsHepatitis B, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryHong Kong
CombinationsYes LamivudineAdefovir Dipivoxil
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsHepatitis B, Chronic

Other Information

ATC CodeN/A
Related LinksN/A